Distribution of PML-RARα NQs after remission induction with chemotherapy or ATRA at clinical remission and after consolidation chemotherapy
| PML-RARα NQ . | Clinical remission3-150 . | After consolidation chemotherapy3-151 . | ||
|---|---|---|---|---|
| CTH . | ATRA . | CTH . | ATRA . | |
| 10−2-10−1 | 3 | 1 | 0 | 0 |
| 10−3-10−2 | 3 | 3 | 1 | 0 |
| 10−4-10−3 | 11 | 2 | 1 | 1 |
| 10−5-10−4 | 9 | 12 | 4 | 2 |
| 10−6-10−5 | 4 | 8 | 1 | 1 |
| 10−7-10−6 | 4 | 5 | 1 | 1 |
| 10−8-10−7 | 1 | 1 | 0 | 0 |
| 10−9-10−8 | 2 | 0 | 5 | 1 |
| Less than 109 | 0 | 0 | 0 | 2 |
| Negative | 13-152 | 63-152 | 12 | 20 |
| Totals | 38 | 38 | 25 | 28 |
| PML-RARα NQ . | Clinical remission3-150 . | After consolidation chemotherapy3-151 . | ||
|---|---|---|---|---|
| CTH . | ATRA . | CTH . | ATRA . | |
| 10−2-10−1 | 3 | 1 | 0 | 0 |
| 10−3-10−2 | 3 | 3 | 1 | 0 |
| 10−4-10−3 | 11 | 2 | 1 | 1 |
| 10−5-10−4 | 9 | 12 | 4 | 2 |
| 10−6-10−5 | 4 | 8 | 1 | 1 |
| 10−7-10−6 | 4 | 5 | 1 | 1 |
| 10−8-10−7 | 1 | 1 | 0 | 0 |
| 10−9-10−8 | 2 | 0 | 5 | 1 |
| Less than 109 | 0 | 0 | 0 | 2 |
| Negative | 13-152 | 63-152 | 12 | 20 |
| Totals | 38 | 38 | 25 | 28 |
P assessed by 2-sided Wilcoxon rank sum test; similar results are obtained when cases are stratified by PML-RARα type or pretreatment WBC count. CTH indicates chemotherapy.
P = .018.
P = .037.
The GAPDH quantity of the 7 PML-RARα− cases was in the same range as the overall study (median, 2.7 × 106; range, 4.4 × 105 to 1.1 × 107).